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Abstract
In recent years recombinant adeno-associated viral vectors (AAV) have become increasingly valuable for in vivo studies in animals, and are also
currently being tested in human clinical trials. Wild-type AAV is a non-pathogenic member of the parvoviridae family and inherently
replication-deficient. The broad transduction profile, low immune response as well as the strong and persistent transgene expression achieved
with these vectors has made them a popular and versatile tool for in vitro and in vivo gene delivery. rAAVs can be easily and cheaply produced in
the laboratory and, based on their favourable safety profile, are generally given a low safety classification. Here, we describe a method for the
production and titering of chimeric rAAVs containing the capsid proteins of both AAV1 and AAV2. The use of these so-called chimeric vectors
combines the benefits of both parental serotypes such as high titres stocks (AAV1) and purification by affinity chromatography (AAV2). These
AAV serotypes are the best studied of all AAV serotypes, and individually have a broad infectivity pattern. The chimeric vectors described here
should have the infectious properties of AAV1 and AAV2 and can thus be expected to infect a large range of tissues, including neurons, skeletal
muscle, pancreas, kidney among others. The method described here uses heparin column purification, a method believed to give a higher viral
titer and cleaner viral preparation than other purification methods, such as centrifugation through a caesium chloride gradient. Additionally, we
describe how these vectors can be quickly and easily titered to give accurate reading of the number of infectious particles produced.
Video Link
The video component of this article can be found at http://www.jove.com/video/3348/
Protocol
See Figure 1 for an illustration summarizing the following protocol.
Safety Note: All material that has been in contact with assembled viral particles needs to be disinfected with Virkon solution or other suitable
disinfectant.
1. Preparation of plasmid DNA stocks (~ 2 days)
2. Preparation of Human Embryonic Kidney 293 (Hek293) cells for transfection (2 - 3 days)
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1. The following plasmids are required 1:
• pRV1 - Containing the AAV2 Rep and Cap sequences
• pH21 - Containing the AAV1 Rep and Cap sequences
• pFdelta6 - Adenovirus-helper plasmid
• AAV plasmid containing the recombinant expression cassette flanked by AAV2 packaging signals (inverted terminal repeats, ITRs)
2. While pFdelta6 should be grown in Stbl2 competent cells to prevent partial deletion, pRV1 and pH21 can be grown in DH5alpha competent
cells. AAV plasmids can be grown in Stbl2 cells if partial deletions occur in DH5alpha cells.
3. Plasmid DNA should be of high quality and free of RNA contaminants. Plasmids can be screened for integrity using the following digests:
• pRV1 - digest with XbaI to give bands of 7.5 kb and 3.8 kb
• pH21 - digest with EcoRI to give bands of 4.5 kb, 2.8 kb and 0.2 kb
• pFdelta6 - digest with HindIII to give bands of 5.5 kb, 3 kb, 3 kb, 2.3 kb and 1.5 kb
1. Plate two 80% confluent 150 cm2 flasks of Hek293 cells into five 15 cm diameter Nunc tissue culture dishes. Cells should be 70 - 80%
confluent before transfection (approximately 48 hours after plating). Culture cells in standard Dulbecco's modified Eagle medium (DMEM)
with low glucose containing 10% foetal calf serum and 100 U/ml penicillin/ 100 μg/ml streptomycin.3. Transfection of viral plasmids (~1 hour for transfection, 3 days for incubation)
4. Lysing of cells and harvesting of rAAVs (2 hours)
5. Heparin column purification of rAAVs (2 - 3 hours)
6. Concentration and sterile filtration of rAAVs (1 hour)
7. Titering of viral stocks (3 days)
This requires a promoter that is active in Hek293 cells driving a reporter gene or an immunocytochemically detectable gene product. When
producing a vector that is not compatible with Hek293 cells other cell lines or primary cell cultures can be used.
8. Anticipated Results
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2. 3 hours before transfection remove DMEM and replace with Iscove's modified Dulbecco's medium (IMDM) containing 5% foetal calf serum.
1. Prepare the following for a single batch (5 x 15 cm tissue culture plates) of virus:
• 62.5 μg AAV plasmid
• 125 μg pFdelta6
• 31.25 μg pRV1
• 31.25 μg pH21
• 1650 μl 2.5 M CaCl2
• 12 ml dH2O
2. In a class 2 tissue culture hood sterile filter the transfection mixture into a 50 ml tube.
3. Whilst vortexing the solution, quickly add 13 ml of 2 x HEPES buffered saline (pH 7.05). Replace lid of 50 ml tube and continue to vortex for
15 seconds. Leave to stand for 1 minute 45 seconds, a fine white precipitate should form.
4. Gently add 5 ml of the transfection solution to each 15 cm tissue culture dish. Swirl plates to mix and return to incubator.
5. 16 hours after transfection remove IMDM medium and replace with DMEM.
1. 72 hours after transfection, remove media from cell culture plates and discard. All waste should be treated with Virkon solution or other
suitable disinfectant.
2. Gently wash the cells in warm 1x phosphate buffered saline (PBS; pH 7.4).
3. Add 25 ml warm PBS to each plate and gently remove cells with a cell scraper. Collect suspension in 50 ml tubes.
4. Pellet cells at 800 x g for 10 minutes.
5. Discard supernatant and resuspend pellet in 150 mM NaCl, 20 mM Tris pH 8.0, use 10 ml per tissue culture plate. Split into two 50 ml tubes.
6. Prepare a fresh solution of 10% sodium deoxycholate in dH2O. Add 1.25 ml of this to each tube for a final concentration of 0.5%. Add
benzonase nuclease to a final concentration of 50 units per ml. Mix tube thoroughly.
7. Incubate at 37°C for 1 hour.
8. Remove cellular debris by centrifuging at 3000 x g for 15 mins. Transfer to fresh 50 ml tube, ensure all cell debris has been removed to
prevent blocking of heparin columns (see step 5). At this stage, the samples can be stored at -20°C before continuing. We have stored
samples for several weeks at -20°C without a reduction in infectivity.
1. Setup HiTrap heparin columns using a peristaltic pump so that solutions flow through the column at 1 ml per minute for steps 5.2 to 5.4. It is
important to ensure no air bubbles are introduced into the heparin column.
2. Equilibrate the column with 10 ml 150 mM NaCl, 20 mM Tris, pH 8.0.
3. Apply 50 ml virus solution to column and allow to flow through.
4. Wash column with 20 ml 100 mM NaCl, 20 mM Tris, pH 8.0.
5. Using a 5 ml syringe continue to wash the column with 1 ml 200 mM NaCl, 20 mM Tris, pH 8.0, followed by 1 ml 300 mM NaCl, 20 mM Tris,
pH 8.0. Discard the flow-through.
6. Using 5 ml syringes and gentle pressure elute the virus from the column by applying:
• 1.5 ml 400 mM NaCl, 20 mM Tris, pH 8.0
• 3.0 ml 450 mM NaCl, 20 mM Tris, pH 8.0
• 1.5 ml 500 mM NaCl, 20 mM Tris, pH 8.0
• Collect these in a 15 ml centrifuge tube.
1. Concentrate vector using Amicon ultra-4 centrifugal filter units with a 100,000 molecular weight cutoff. Load 4 ml of column eluate into the
concentrator and centrifuge at 2000 x g for 2 minutes (at room temperature). Discard flowthrough and reload concentrator with remaining
virus solution and repeat centrifugation. The concentrated volume should be approximately 250 μl. If concentrated volume is significantly
more than this, discard the flow through and continue to centrifuge in one minute steps until volume is approximately 250 μl.
2. Add 250 μl of PBS to virus for a final volume of 500 μl and remove from concentrator.
3. Filter vector through a 13 mm diameter 0.2 μm syringe filter. Vector should be aliquoted and stored at -80°C until required.
1. Prepare 18 poly-L-lysine coated glass coverslips or 18 wells of Nunc chamber slides by seeding Hek293 cells so that they are 40 - 50%
confluent. For titration of Cre-dependent rAAVs use Hek293 cells that stably express Cre recombinase 2.
2. Infect each well with serial dilutions of the AAV vector (Fig 2A). Use 3 wells per dilution. We routinely add virus directly to each well.
3. After 72 hours fix Hek293 cells by adding an equal volume of 4% paraformaldehyde (PFA) to medium (giving a final concentration of 2% PFA)
for ten minutes at room temperature.
4. Wash cell three times in PBS, rinse in dH2O and coverslip.
5. Count the number of transduced cells from the three wells that have the highest dilution factor, but still contain infected cells, find the average
of these and multiply by the dilution factor to give the number of infectious units per microliter (Fig 2B).Hek293 cells transduced with a virus encoding enhanced green fluorescent protein (eGFP) are shown in Figure 2B. We generally achieve
consistent titers of around 6 x 106 infectious particles per micro litre. We routinely use these vectors for stereotaxic injection into the adult rodent
brain. This provides a powerful technique for region-specific gene expression 2. To combine this region specificity with cell-type selective gene
expression we inject Cre recombinase-dependent rAAVs into target regions of Cre-transgenic mice 2. Figure 2C-E shows examples of stereotaxic
injections of Cre-dependent rAAVs encoding eGFP into different brain regions of adult parvalbumin-Cre transgenic mice 3.
 
Figure 1. Schematic illustration of the protocol for rAAV production. 1.) Hek293 cells are plated and grown to 70 - 80% confluence. 2.) AAV and
helper plasmids are prepared and transfected into Hek293 cells. 3.) Medium is changed back to DMEM 16 hours after transfection and Hek293
cells are cultured for another 56 hours. 4.) Hek293 cells are harvested and lysed. rAAV vectors are separated from cell debris by centrifugation.
5.) Viral particles are purified through heparin columns before concentration and sterilisation. 6.) Hek293 cells are grown on 24 well plates and
infect with serial dilutions of the AAV vector to determine the number of infectious units.
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Figure 2. Titering and in vivo application of rAAV1/2. (A) Setup of Hek293 cells for measuring viral titer. Hek293 cells are transduced with serial
dilutions of rAAVs. C, uninfected control; N, 1 μl of undiluted viral stock. (B) Hek293 cells infected with rAAVs expressing eGFP. (C-E) Viral eGFP
expression is restricted to Cre-expressing neurons in different target regions of parvalbumin-Cre transgenic mice after stereotaxic injection of
Cre-activated rAAVs. Examples images show GFP immunoreactivity in (C) the reticular thalamus and globus pallidus, (D) the dentate gyrus and
(E) the CA1 region of the hippocampus. DG, dentate gyrus; RT, reticular thalamic nucleus; GP, globus pallidus. Scale bars: B, 500 μm; C, 100
μm; D, 100 μm; E, 500 μm.
rAAV vectors are becoming increasingly valuable for in vivo studies in animals. Here, we have described a simple and inexpensive protocol for
producing rAAVs, which may facilitate the widespread application of this useful vector by avoiding the costly outsourcing of virus production to
companies. The protocol (based on reference 1) describes the production of chimeric rAAV1/2 vectors containing capsid proteins from both
parental serotypes at equal ratios 4. The purification of the rAAV vectors by binding to heparin columns relies on the expression of AAV2 capsid
proteins, but can be combined with serotypes other than AAV1 outlined here. Additionally, AAV6 has been reported to bind to heparin, although
with a reduced affinity, and could potentially be purified with heparin columns using this procedure 5,6. It should be noted however, that other
serotypes will require different concentrations of NaCl for heparin column elution 5,7.
Packaging rAAV genomes was shown to be optimal between 4.1 and 4.9 kb with a sharp reduction in packaging efficiency up to 5.2 kb 8. This
packaging limit can be considered the largest disadvantage of the rAAV system, since cell type-specific regulation of transgene expression is
usually achieved by large cis acting elements which can not be accommodated within the small AAV particles. To overcome low titer batches,
such as those resulting from attempting to package genes that are close to the AAV packing limit we are combining separate viral batches
concentrated to 250 μl into one 500 μl batch, rather than adding PBS as outlined in step 6.3. Reliable cell-type specific transduction can be
achieved by combining Cre-driver mice and conditional rAAV cassettes (see below) to avoid stretching the packaging limit.
Of note, while this protocol attempts to provide easy-to-follow instructions on the production of high titer rAAV, it requires the presence of AAV2
capsid protein moieties for purification by heparin affinity chromatography. Serotypes other than AAV2 must be purified using alternate procedures
9. One advantage of heparin column purification is it is believed to produce AAV vectors that have greater infectivity rate than those produced
using a caesium chloride gradient 10. However, there are also some drawbacks to this method. For example, other proteins that bind heparin may
also be present in the purified viral stock. While the tropism of heparin-purified vectors can be influenced by the vector titer10, our approach to
specifically target either excitatory20 or inhibitory neurons (Fig. 2) employs Cre-induced activation of AAV-mediated transgene expression and is
titre-independent. An alternative to heparin column purification is the use of an iodixanol density gradient, which produces a higher viral titer and
purer preparation than the use of a caesium chloride gradient 10. This method can also be combined with heparin column purification to produce a
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. Therefore, careful consideration needs to be taken by individual groups as to which viral purification
method is best for their particular downstream application.
The most common problem associated with this protocol is low viral titer. In our experience this can usually be traced to low transfection
efficiency, or the elution of virus from the heparin columns. All transfection materials should be at room temperature before transfection, and test
transfections should be performed to find the optimal conditions in each laboratory. Other methods of transfection, such as lipofectamine, are
highly efficient, but can be prohibitively expensive. Additionally, the concentration and pH of the heparin column elution solutions is critical for
complete elution of virions from heparin columns without damage. Another important point is that the packaging cells must adhere well to the
surface of the tissue culture dishes. If the cells detach at some stage during the procedure it is advised to terminate the experiment and defrost a
new vial of cells.
Spatio-temporal control of transgene expression in rodents is easily achieved by accurate anatomical targeting and the developmental stage of
the animal. Efficient AAV-mediated gene transfer has been shown in utero 12,13. In the adult brain, the area infected with rAAV particles after
stereotaxic injection can be adjusted from very small targeted regions, to much larger areas not only by changes in the viral titer but also by
altering the injection parameters. These include the volume and speed of injections and the inclusion of the polyol mannitol with the virus
suspension 14. Mannitol can also be used to enhance infection of a variety of tissues after systemic rAAV injection 15.
The packaging capacity of rAAV (approximately 4.7 kb) is probably the most limiting factor in terms of the genes that can be expressed from
these viral vectors. However, recent studies have shown that this can be partially overcome by splitting larger genes or expression cassettes into
separate rAAV vectors and introducing a bridging sequence, initiating gene expression when virions infect the same cell 16. Expression levels of
genes carried by rAAV vectors can also be greatly enhanced by using self-complimentary rAAV vectors 17. Stereotaxic injection of rAAV vectors
provides a rapid, inexpensive and powerful method for inducing gene expression in a region-specific manner. In combination with 2nd generation
RNA interference strategies 18 rAAVs can also be used for region-specific gene-knock down. rAAVs can be combined with Cre-transgenic mice or
cell-type specific promoters to achieve circuit- and cell-type-specific gene expression, permitting genetic manipulations with high spatial resolution
2,19-21, while fitting rAAVs with e.g. the tet system adds temporal control over virus-mediated gene expression 22,23.These examples illustrate the
enormous combinatorial potential of these vectors and predict a rapid increase in rAAV-based studies over the years to come.
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